Mayo Clinic Engineers DNA 'Tags' That Pinpoint Hidden 'Zombie Cells' Driving Aging

Researchers at Mayo Clinic have engineered tiny synthetic DNA molecules that can reliably tag the "zombie cells" believed to drive much of human aging, a step that has frustrated biologists for two decades and could finally open the door to a new generation of drugs aimed at age-related disease. The findings, published Thursday, identify a class of molecules called aptamers that bind selectively to senescent cells while sparing the healthy tissue around them — potentially allowing future therapies to destroy zombie cells with surgical precision.

Senescent cells are cells that have stopped dividing but refuse to die. They accumulate in tissue as humans age and pump out a cocktail of inflammatory chemicals that researchers have linked to Alzheimer's disease, arthritis, fibrosis, certain cancers and the general frailty of old age. Wiping them out in laboratory mice has been shown to extend healthy lifespan, but in humans the cells are notoriously difficult to find: they hide among healthy neighbors and lack a single, reliable surface marker that drugs can use to recognize them. "The biggest problem in this whole field has been delivery," Dr. James Maher, the senior author of the Mayo study, said in an interview. "You can have a drug that kills senescent cells, but if you can't tell those cells apart from the healthy ones, you also kill what you need."

The Mayo team, led by Maher and graduate researcher Tabor Whitney, screened more than 100 trillion random DNA sequences searching for short, folded strands that would latch onto proteins specific to senescent cells. After several rounds of selection in mouse cells, the group identified several rare aptamers that bind tightly to those surface proteins and not to similar markers on healthy cells. Whitney first pitched the screening approach as a long-shot idea during a lab meeting; Maher said the team almost dismissed it before deciding to test it as a low-cost side project. The results stunned the group: the aptamers bound their targets with affinity competitive with the best monoclonal antibodies, but at a fraction of the manufacturing cost.

Unlike antibodies, aptamers are small, stable and inexpensive to produce, and they can in principle be wired to a drug payload, a radioactive tracer or a gene-editing tool. That makes them attractive candidates as molecular "delivery trucks" that could carry senolytic drugs — therapies that destroy senescent cells — directly to the cells that need to be cleared. The Mayo group has already begun work to fuse the new aptamers to existing senolytic compounds in animal models and to develop imaging agents that could let physicians see where senescent cells are clustered in living patients for the first time.

Independent researchers said the study is an important early step, but cautioned that translating it to humans will take years. The current findings are limited to mouse cells, and the proteins that mark senescent cells in mice are not identical to those in human tissue. "This is a beautiful proof of concept," said Dr. Judith Campisi, a longtime senescence researcher at the Buck Institute for Research on Aging in California, who was not involved in the work. "The next big question is whether the same approach will identify the right targets in humans. If it does, we are looking at a real shift in how we think about treating age-related disease."